<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00121550</url>
  </required_header>
  <id_info>
    <org_study_id>1997-08-DP-42-RKF-13 CLARICOR;</org_study_id>
    <secondary_id>REC: KF01-076/99</secondary_id>
    <secondary_id>DDPA: 2001-41-1496,</secondary_id>
    <secondary_id>DMA: 2612-975</secondary_id>
    <nct_id>NCT00121550</nct_id>
  </id_info>
  <brief_title>The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease</brief_title>
  <official_title>The Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease - a Randomized, Placebo Controlled, Double Blinded, Multicentre, Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen Trial Unit, Center for Clinical Intervention Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Hospital Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 1991 Pharmacy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen Trial Unit, Center for Clinical Intervention Research</source>
  <brief_summary>
    <textblock>
      A growing body of evidence links Chlamydia pneumoniae to the progression of coronary heart
      disease. The purpose of this study is to determine the positive and negative effect of 14
      days treatment with clarithromycin 500 mg daily in patients already suffering from stable
      coronary heart disease. The participants will be followed for at least two years after the
      treatment.

      Abbott Laboratories supplied Clarithromycin and placebo tablets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Basic science suggests a fundamental role for inflammation in mediating all stages of
      coronary heart disease (CHD), and a large number of clinical studies have reported an
      association between markers of inflammation and CHD. Consequently, infectious agents have
      been proposed as promoters of atherosclerosis and/or acute coronary syndrome (ACS). Many
      studies have suggested a relation between Chlamydia pneumoniae (C. pneumoniae) infection and
      CHD, and C. pneumoniae has been demonstrated in atherosclerotic tissue.

      Macrolide antibiotics are effective in eradication of C. pneumoniae from atherosclerotic
      plaques. Two small trials showed significant beneficial effects of macrolides on
      cardiovascular morbidity in patients with ACS. To corroborate and extend these findings, we
      undertook a randomised, placebo-controlled trial with clarithromycin in patients with stable
      CHD in order to test the hypothesis that intervention with a macrolide would reduce
      cardiovascular risk with regard to mortality and morbidity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1999</start_date>
  <completion_date type="Actual">September 2002</completion_date>
  <primary_completion_date type="Actual">April 2000</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite consisting of: death regardless of cause</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>non-fatal AMI or</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>unstable angina pectoris whichever occurred first</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite of: cardiovascular death</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-fatal AMI or</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unstable angina pectoris whichever occurred first</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4372</enrollment>
  <condition>Heart Disease</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clarithromycin</intervention_name>
    <arm_group_label>Clarithromycin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients aged 18 to 85 years and

          -  previous acute myocardial infarction (AMI) or

          -  previous or present angina pectoris and

          -  signed informed concent

        Exclusion Criteria:

          -  AMI or unstable angina pectoris within the last three months

          -  revascularisation (PTCA or CABG) within the preceding six months

          -  severe heart failure (New York Heart Association (NYHA) functional class IV)

          -  known impaired renal or hepatic function

          -  active malignancy

          -  intolerance to macrolides

          -  treatment with methylxanthines, carbamazepine, cisapride, astemizole, terfenadine, or
             coumarin anticoagulants

          -  earlier inclusion in the CLARICOR Trial or participation in another drug trial within
             four weeks

          -  participation in other clinical trials within one month before this trial

          -  individuals incapable of managing own affairs or not able to sign written consent

          -  lack of written consent

          -  women of childbearing age not using reliable contraceptives

          -  breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Jespersen, DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology Y, Bispebjerg Hospital, Bispebjerg Bakke 23, DK 2400 Copenhagen NV, Denmark.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Gluud, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Copenhagen Trial Unit, Center of Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, DK-2100 Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Amager Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Frederiksberg Hospital</name>
      <address>
        <city>Frederiksberg</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H:S Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Hansen S, Als-Nielsen B, Damgaard M, Helø OH, Petersen L, Jespersen CM. Intervention with clarithromycin in patients with stable coronary heart disease. The CLARICOR Trial Design. Heart Drug 2001;1:14-9.</citation>
  </reference>
  <results_reference>
    <citation>Jespersen CM, Als-Nielsen B, Damgaard M, Hansen JF, Hansen S, Helø OH, Hildebrandt P, Hilden J, Jensen GB, Kastrup J, Kolmos HJ, Kjøller E, Lind I, Nielsen H, Petersen L, Gluud C; CLARICOR Trial Group. Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial. BMJ. 2006 Jan 7;332(7532):22-7. Epub 2005 Dec 8. Erratum in: BMJ. 2006 Jan 21;332(7534):151.</citation>
    <PMID>16339220</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2005</study_first_submitted>
  <study_first_submitted_qc>July 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2005</study_first_posted>
  <last_update_submitted>August 10, 2016</last_update_submitted>
  <last_update_submitted_qc>August 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen Trial Unit, Center for Clinical Intervention Research</investigator_affiliation>
    <investigator_full_name>Christian Gluud</investigator_full_name>
    <investigator_title>MD, DMSc</investigator_title>
  </responsible_party>
  <keyword>Coronary heart disease</keyword>
  <keyword>Clarithromycin</keyword>
  <keyword>Macrolides</keyword>
  <keyword>Cardiovascular mortality</keyword>
  <keyword>Chlamydia pneumoniae</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

